UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

European urology, 2022-01, Vol.81 (1), p.50-61

2022

Volltextzugriff (PDF)

Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?

European urology, 2012-07, Vol.62 (1), p.68-75

2012

Volltextzugriff (PDF)

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

European urology, 2020-03, Vol.77 (3), p.320-330

2020

Volltextzugriff (PDF)

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score

European urology, 2023-05, Vol.83 (5), p.432-440

2023

Volltextzugriff (PDF)

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up

European urology, 2014-11, Vol.66 (5), p.829-838

2014

Volltextzugriff (PDF)

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

European urology, 2008-05, Vol.53 (5), p.941-949

2008

Volltextzugriff (PDF)

Can Radical Prostatectomy Benefit Patients Despite the Presence of Regional Metastases?

European urology, 2010-05, Vol.57 (5), p.762-763

2010

Volltextzugriff (PDF)

Robot-Assisted Cystectomy: Does It Meet Expectations?

European urology, 2010-08, Vol.58 (2), p.203-204

2010

Volltextzugriff (PDF)

Reply to Magdi Mounir Kirollos’ Letter to the Editor re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer Not Suitable for Local Curative Treatment (EORTC 30891). Eur Urol 2008;53:941–9 and re: John Anderson. Androgen Deprivation Therapy—It's All a Matter of Timing. Eur Urol 2008;53:869–71

European urology, 2009-02, Vol.55 (2), p.e45-e46

2009

Volltextzugriff (PDF)

Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy

European urology, 2006-11, Vol.50 (5), p.887-889

2006

Volltextzugriff (PDF)

Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostate Cancer: An EORTC Feasibility Study

European urology, 2003-11, Vol.44 (5), p.505-511

2003

Volltextzugriff (PDF)

Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 MO Prostate Cancer Without Local Treatment of the Primary Tumour : Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)

European urology, 2009, Vol.55 (1), p.14-22

2009

Volltextzugriff (PDF)

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 MO Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

European urology, 2008, Vol.53 (5), p.941-949

2008

Volltextzugriff (PDF)

Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863

European urology, 2002-08, Vol.42 (2), p.125-132

2002

Volltextzugriff (PDF)

Tissue Polypeptide-Specific Antigen (TPS) Determinations before and during Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostatic Carcinoma

European urology, 2003, Vol.43 (1), p.31-38

2003

Volltextzugriff (PDF)

Strontium89 Chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer : A phase iii study of the European Organisation for Research and Treatment of Cancer Genitourinary Group

European urology, 2003-11, Vol.44 (5), p.519-526

2003

Volltextzugriff (PDF)

Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Commentary

European urology, 2003, Vol.44 (2), p.182-189

2003

Volltextzugriff (PDF)

Metastatic prostate cancertreated by Flutamide versus Cyproterone acetate: Final analysis of the European organization for research and treatment of cancer (EORTC) protocol 30892

European urology, 2004, Vol.45 (4), p.457-464

2004

Volltextzugriff (PDF)

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study

European urology, 2003, Vol.44 (5), p.505-511

2003

Volltextzugriff (PDF)

Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma

European urology, 2003, Vol.43 (1), p.31-38

2003

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieEuropean Urology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)

Sprache

Englisch
(21)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Urology & Nephrology
(14)
Male
(11)
Prostatic Neoplasms - Pathology
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Prostate Cancer
(7)
Aged
(6)
Nephrology. Urinary Tract Diseases
(6)
Treatment Outcome
(6)
Urology
(6)
Middle Aged
(5)
Tumors Of The Urinary System
(5)
Urinary Tract. Prostate Gland
(5)
Prostatic Neoplasms - Mortality
(4)
Tumors
(4)
Aged, 80 And Over
(3)
Androgen Antagonists - Administration & Dosage
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect
(23)
Elsevier ScienceDirect Journals Complete
(23)
MEDLINE
(14)
IngentaConnect Journals
(6)

Menü

Weitere Dienste

Einstellungen

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials

Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440]

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

Can Radical Prostatectomy Benefit Patients Despite the Presence of Regional Metastases?

Robot-Assisted Cystectomy: Does It Meet Expectations?

Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy

Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostate Cancer: An EORTC Feasibility Study

Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 MO Prostate Cancer Without Local Treatment of the Primary Tumour : Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 MO Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863

Tissue Polypeptide-Specific Antigen (TPS) Determinations before and during Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostatic Carcinoma

Strontium89 Chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer : A phase iii study of the European Organisation for Research and Treatment of Cancer Genitourinary Group

Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Commentary

Metastatic prostate cancertreated by Flutamide versus Cyproterone acetate: Final analysis of the European organization for research and treatment of cancer (EORTC) protocol 30892

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study

Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma

Aktive Filter

Suchergebnisse filtern